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Abstract
Pancreatic cancer is an especially deadly form of cancer with a survival rate <2%. Pancreatic
cancers respond poorly to existing chemotherapeutic agents and radiation, and progress for the
treatment of pancreatic cancer remains elusive. To address this unmet medical need, a better
understanding of critical pathways and molecular mechanisms involved in pancreatic tumor
development, progression and resistance to traditional therapy is therefore critical. Reduction-
oxidation (redox) signaling systems are emerging as important targets in pancreatic cancer. AP
endonuclease1/ Redox effector factor 1 (APE1/Ref-1) is upregulated in human pancreatic cancer
cells and modulation of its redox activity blocks the proliferation and migration of pancreatic
cancer cells as well as pancreatic cancer-associated endothelial cells (PCECs) in vitro. Modulation
of APE1/Ref-1 using a specific inhibitor of APE1/Ref-1’s redox function, E3330 leads to a
decrease in transcription factor activity for NFκB, AP-1, and HIF1 in vitro. This study aims to
further establish the redox signaling protein APE1/Ref-1 as a molecular target in pancreatic
cancer. Here, we show that inhibition of APE1/Ref-1 via E3330 results in tumor growth inhibition
in cell lines as well as pancreatic cancer xenograft models in mice. Pharmacokinetic (PK) studies
also demonstrate that E3330 attains >10 μM blood concentrations and is detectable in tumor
xenografts. Through inhibition of APE1/Ref-1, the activity of NFκB, AP-1, and HIF1α which are
key transcriptional regulators involved in survival, invasion and metastasis is blocked. These data
indicate that E3330, inhibitor of APE1/Ref-1, has potential in pancreatic cancer and clinical
investigation of APE1/Ref-1 molecular target is warranted.
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INTRODUCTION
Pancreatic cancer is a particularly insidious form of cancer with the worst 5-year survival
rate of any cancer at <2%.(1) There is no early detection method for pancreatic cancer,
which often displays only non-specific symptoms such as abdominal pain, weight loss, and
vomiting, until the cancer is well-advanced.(2) Pancreatic cancers are hypoxic tumors that
respond poorly to existing chemotherapeutic agents and radiation.(3) NFκB and HIF-1α
have been identified as leading drivers of cell growth in pancreatic cancer; both are under
APE1/Ref-1 redox signaling control which is the focus of our studies.(4-6)
Cellular response to base DNA damage is a highly regulated and complex biological
process. APE1/Ref-1 is a vital protein in this process and acts as a master regulator of the
DNA damage response by contributing to the maintenance of the genome. APE1/Ref-1 is a
dual function protein involved in base excision repair (BER) pathways of DNA lesions, as
the major apurinic/apyrimidinic endonuclease, and in eukaryotic transcriptional regulation
of gene expression as a reduction-oxidation (redox) factor. APE1/Ref-1 can stimulate DNA
binding activity of numerous transcription factors that are involved in cancer promotion and
progression such as HIF-1α, NFκB, AP-1, p53 and others. (6-13) The functional regions of
APE1/Ref-1, redox and DNA repair, are completely independent in their function; i.e.,
mutations of the cysteine at position 65 removes the redox function but does not affect the
DNA repair function, and vice versa. (14) While the DNA repair active site of APE1/Ref-1
is delineated, (15) the redox region is less obvious. Recently the mechanism of APE1/Ref-1
redox structure-function is being elucidated.(16-18) APE1/Ref-1 redox inhibitor, E3330
recognizes an alternate, redox active conformation of APE1/Ref-1, and potentially inhibits
its redox activity by inducing disulfide bond formation within APE1/Ref-1.(16)
To investigate the role of redox regulation by APE1/Ref-1 in pancreatic cancer, we utilized
E3330, a highly selective inhibitor of APE1/Ref-1 redox function. Originally discovered in a
search for NFκB inhibitors, E3330 was used in liver inflammation and hepatitis, but never
investigated for its therapeutic potential in cancer.(19, 20) We previously demonstrated that
APE1/Ref-1 is upregulated in human pancreatic cancer cells and modulation of its redox
activity blocks the proliferation and migration of pancreatic cancer cells (21, 22) as well as
pancreatic cancer-associated endothelial cells (PCECs) in vitro.(23) Here we study the
effects of redox signaling through APE1/Ref-1 in animal models of pancreatic cancer. The
effectiveness of E3330 in vivo is demonstrated with good pharmacokinetic (PK) and
pharmacodynamic properties (PD) as well as tumor growth reduction. Our in vitro data
supports the in vivo results showing that blocking the redox activity of APE1/Ref-1 inhibits
the proliferation and adhesion of pancreatic cancer cell lines, arrests cell cycle progression,
and decreases the transcriptional activation of three major transcription factors known to be
important in pancreatic cancer progression, survival and metastasis (NFκB, HIF-1α and
AP-1(24)). In conclusion, this is the first specific APE1/Ref-1 redox inhibitor that
demonstrates in vivo effectiveness and further work on this and other related compounds
will allow the development of “first in class” and “first in human” agents for the treatment
of pancreatic cancer.
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MATERIALS AND METHODS
Cell lines
Panc-1 and PaCa-2 were purchased from and authenticated by ATCC (Manassas, VA). Both
were maintained at 37°C in 5% CO2 and grown in DMEM (Invitrogen; Carlsbad, CA) with
10% Cosmic Calf Serum (Hyclone; Logan, UT).
Proliferation of PaCa-2 and Panc-1 cells
The proliferative capacity of PaCa-2 and Panc-1 cells was assessed using Trypan Blue
(0.4%; Invitrogen; Carlsbad, CA) and the xCELLigence system (25, 26), and E3330 was
synthesized as previously described.(16, 26) For Trypan Blue assays, PaCa-2 and Panc-1
cells were treated with E3330 for 72- and 48-h, respectively. Effects of E3330 on the growth
were determined using the xCELLigence DP System (Roche Applied Science, Indianapolis
IN).(25) Following background reading, cells (PaCa-2: 3,000 and Panc-1: 4,000 cells/well)
were plated in 16-well plates in 100 μl volume. After adding cells to the wells, plates were
kept at room temperature for 30 minutes after which they were inserted into the cradles.
Cells were allowed to grow for 18 – 22 h before E3330 was added. Continuous impedance
measurements were then monitored over 72 h. Assays were performed in triplicate.
Adhesion assay
For the adhesion assays,(27) serum-free media containing increasing concentrations of
E3330 was added to each well in triplicate. A background reading was taken and then
PaCa-2 or Panc-1 cells were added in complete media. Plates were kept at room temperature
for 15 min and inserted into the cradle. Continuous impedance measurements were taken
every 15 – 30 min over 30-h.
Western blot analysis
Cells were harvested, lysed in RIPA buffer (Santa Cruz Biotechnology; Santa Cruz, CA),
and protein was quantified and electrophoresed on a 12% SDS-polyacrylamide gel. The
following antibodies were used: APE1/Ref-1 (Novus Biologicals; Littleton, CO), PARP-1
(Cell Signaling Technology Inc.; Danvers, MA), tubulin (Sigma Aldrich), p21 and p27
(Santa Cruz Biotechnology).(22)
Apoptosis Assays via Alexa Fluor 488-Conjugated Annexin-V (Annexin-V) / Propidium
Iodide Staining
Apoptosis was assayed 48-h after E3330 treatment. Cells were trypsinized, pelleted, washed
in ice-cold PBS and resuspended in 1x Binding Buffer. Apoptosis was analyzed using the
Alexa Fluor® 488 Annexin-V Vybrant® Apoptosis Assay Kit in combination with
propidium iodide (PI) (Molecular Probes; Eugene, OR) as previously described (9).
Cell cycle staining via BrdU
To stain the cells for DNA content and analyze the movement of cells through G0/G1, S and
G2/M, cells were plated, allowed to attach overnight, and treated with E3330 in serum free
media for 24 hrs. Following treatment, cells were processed according to the manufacturer’s
directions (BD Pharmingen; San Diego, CA). (9)
Transient Luciferase Reporter Assays
Panc-1 and PaCa-2 cells were co-transfected with constructs containing luciferase driven by
NFκB, AP-1, or HIF1 (pLuc-MCS with the NFκB, AP-1, or HIF1 responsive promoter;
PathDetect cis-Reporting Systems, Stratagene, La Jolla, CA(5)) and a Renilla luciferase
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control reporter vector pRL-TK (Promega Corp., Madison, WI) in a 20:1 ratio by using
lipofectamine TM 2000 (Invitrogen Life Technologies, Carlsbad, CA). After transfection for
16-h, cells were treated with E3330 in serum free media for 24-h (for HIF1 drug added
immediately before placement in hypoxic chamber). Firefly and Renilla luciferase activities
were assayed by using the Dual Luciferase Reporter Assay System (Promega Corp.) with
Renilla luciferase activity for normalization in a 96-well microtiter plate luminometer
(Thermolabs Systems, Franklin, MA). Each time, a “media only” control was included, and
the final data is expressed as the fold change of the relative luciferase units (RLU) compared
to the vehicle control, DMSO. DMSO concentration was equivalent in all samples and the
final concentration was less than 0.25%. All of the transfection experiments were performed
in triplicate and repeated at least 3 times in independent experiments.
Stable Cell lines for Reporter assays
Using lentiviral transcriptional reporter vectors, pGreenFire-NFκB, pGreenFire-HIF1, and
pGreenFire-mCMV (negative control), from System Biosciences Inc. (Mountainview, CA),
we transfected HEK293-T cells (Lonza, Inc. Allendale, NJ) with the constructs and collected
the media containing the viral supernatants. To generate stably expressing reporter cell lines,
we infected pancreatic cancer cells with the viral supernatant and selected the cells with
puromycin (5 ng/mL) for 5 days. For the experiments inducing NFκB activity via TNFα,
Panc-1 and PaCa-2 were treated with E3330 for 24-h in serum free media and then treated
with TNFα for 6-h. Cells were then assayed for luciferase activity as described above except
the normalization was done using MTS-based assay. For the MTS assay (11, 22), 7.5×104
cells per 96-well were plated in parallel with the cells for luciferase assay, allowed to adhere
overnight, and then treated with E3330 and TNFα as above. Alongside the luciferase assay,
MTS reagent was added to the 96-well plates for 2-h. Values were standardized to wells
containing media alone and then used to account for effects of drug treatment on the cells.
qRT-PCR Reactions
qRT-PCR was used to measure the mRNA expression levels of HIF1 downstream target,
CA-IX (carbonic anhydrase-IX) gene. PaCa-2 and Panc-1 were treated with increasing
amounts of E3330 in the presence or absence of hypoxia (1% O2) for 24-h, then total RNA
was extracted from cells using the Qiagen RNeasy Mini kit (Valencia, CA) according to the
manufacturer’s instructions(28).The extracted RNA was quantified by a Qubit fluorometer
(Invitrogen Corp, Carlsbad, CA). First-strand cDNA was obtained from RNA using random
hexamers and MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA).
Quantitative PCR was performed using Taqman Gene Expression assays and Universal PCR
master mix (Applied Biosystems) in a 7900HT Sequence detection system (Applied
Biosystems). The relative quantitative mRNA level was determined using the comparative
Ct method using 18S rRNA as the reference gene(28-30).The primers for CA-IX and 18S
are commercially available (Applied Biosystems). Experiments were performed in triplicate
for each sample.
PK Studies in NOD/SCID mice
NOD/SCID mice were administered 25mg/kg E3330 i.p. in DMSO(9%)/sterile saline for
initial PK studies. To determine PK parameters, following administration of E3330, blood
was collected via tail vein at multiple timepoints between 0.5 – 36-h following
administration. We collected two samples (~25 μL) per mouse with each sample collected at
least 6-h apart. Following half-life determination, a dosing regimen for the tumor studies
was established in mice that consisted of two doses of E3330 each day, approximately 8-h
apart for 14 days.
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E3330 was quantified in plasma and solid tissue using an internal standard
(bromomethylcoumarin, BMC), liquid-liquid extraction with ethyl acetate and HPLC-MS/
MS (Agilent HPLC, Applied Biosystems API 4000). The HPLC was run in isocratic mode
using acetonitrile:5mM ammonium acetate (60:40, v/v). The API 4000 was run in negative
mode for E3330 (Q1/Q3: 377/333) and positive mode for BMC (Q1/Q3, 301/220). The
lower limit of quantification was 1 ng/mL using 10 μL of blood or plasma. For E3330 in
solid tissue, tissue was weighed, reconstituted with phosphate buffer (100 mM NaPO4, pH =
7.4) to up to two mL of total volume, and homogenized by a hand held homogenizer. An
aliquot of the homogenate was used for the extraction. Tissue concentration is expressed in
ng/g tissue.
Pharmacokinetic parameters for E3330 including area under the curve (AUC), area under
the moment curve (AUMC), and t½ were estimated using noncompartmental methods with
Excel®. The maximum plasma concentration (Cmax) and time of Cmax (tmax) were obtained
from the data. The AUC from zero to infinity (AUC0-∞) was estimated from the AUC0-t
(time zero to the last quantifiable concentration Clast) and the AUC from Clast to infinity,
Clast/kel, where kel is the rate constant of elimination. The AUMC0-∞ was estimated by an
analogous manner. The systemic clearance (Cl/F, where F = bioavailability) of E3330 was
calculated from the dose and AUC0-∞. The apparent volume of distribution (Vdss) was
estimated by the following equation: (dosage/AUC0-∞) x (AUMC0-∞/AUC0-∞)
Animals
All animal studies were conducted under the guidelines of the National Institutes of Health
and were approved by the Institutional Animal Care and Use Committee of Indiana
University School of Medicine and Johns Hopkins School of Medicine. Animals were
maintained under pathogen-free conditions and a 12 h light-dark cycle.
For the patient-derived xenografts, 6-week-old female nu/nu athymic mice (Harlan) were
utilized while PaCa-2 cells were grown as ectopic xenografts in NOD/scid mice. NOD/scid
(NOD.CB17-Prkdcscid/J) mice were obtained from the In Vivo Therapeutics Core of the
Indiana University Simon Cancer Center.
Establishment of ectopic xenografts from PaCa-2 cells—PaCa-2 cells (2.5×106) in
0.2 ml of DMEM media were implanted subcutaneously (s.c.) into the right flanks of NOD/
SCID mice. E3330 was dissolved in 4% CremophorEL:EtOH (1:1) / saline solution or
methylcelluose (0.5%, Sigma St. Louis, MO). When tumor volumes were greater than
100mm3, E3330 was administered twice daily, 8 hours apart, at 25 mg/kg for 10 - 12 days (5
days on and 2 days off schedule). Tumors were measured biweekly and followed for ~6
weeks. Tumor volumes were monitored by caliper measurement [tumor volume = length x
(perpendicular width)2 x 0.5] and the average tumor volume in mm3 for each treatment
group was plotted. Treatment corresponds to Days 1 – 15. Average tumor volume ± SE for
the vehicle- and E3330-treated PaCa-2 xenografts (n=7) was analyzed by statistical analysis.
Ectopic xenograft established from patient-derived cells—Fresh pancreatic cancer
specimens resected from patients at the time of surgery, with informed written patient
consent, were implanted s.c. into the flanks of 6-week-old female nu/nu athymic mice
(Harlan). The patients had not undergone chemotherapy or radiation therapy before surgery.
Grafted tumors were subsequently transplanted from mouse to mouse and maintained as a
live PancXenoBank according to an IRB approved protocol. Panc253 xenograft was used for
the study. When tumors reached a volume of ~200 mm3, mice were individually identified
and randomly assigned to treatment groups, with 5–6 mice (8-10 evaluable tumors) in each
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group: 1) control; 2) E3330, administered twice daily, 8 hours apart, at 25 mg/kg for a total
of 10 doses (5 days on 2 days off, 5 days on and 2 days off schedule).
Statistics
For the PaCa-2 xenograft data, all data points for vehicle and E3330-treated mice were
analyzed. Continuous variables were summarized by typical parameters such as mean,
standard deviation and range and compared using two-sample T test (if the normality
assumption holds) or Wilcoxon rank-sum test (if the normality assumption does not hold).
Normality of distribution was determined using the Kolmogorov-Smirnov goodness-of-fit
test. Categorical data were summarized by frequency and percentage and analyzed using the
Chi-square or Fishers exact test, as appropriate. A linear mixed-effects model was fit to the
repeatedly collected tumor size data. The fixed effects include experimental group, and
distinct linear, quadratic and cubic effects of time for each of the two groups. The random
effects include intercept and linear effect of time (31). The model was estimated using SAS
9.2 (SAS Institute, Inc., Cary, NC). A p-value less than 0.05 was considered statistically
significant.
RESULTS
APE1/Ref-1 redox inhibitor, E3330 inhibits the proliferation and ability of pancreatic cancer
cell lines to adhere but does not induce apoptosis
We tested the effect of APE1/Ref-1 redox inhibition on the growth of pancreatic cancer cells
using a trypan blue assay. E3330 was found to effectively slow the growth rate of cells in a
dose-dependent manner (Figure 1A), with an ED50 of 135 and 87 μM for PaCa-2 and
Panc-1, respectively. The ability of E3330 to inhibit proliferation and/or reduce survival of
PaCa-2 and Panc-1 cells was further characterized using the xCELLigence DP system
(Roche, Indianapolis IN). This system measures a dimensionless parameter called Cell Index
(CI), which integrates information on cell viability, number, morphology, and adhesion.(27)
In this assay, E3330 dramatically reduced CI of PaCa-2 and Panc-1 cells efficiently and in a
dose-dependent manner, suggesting that E3330 inhibits growth and proliferation of
pancreatic cancer cells as well as affects morphology and adhesion (Figure 1B). The ED50
of E3330 was reduced by 2-fold using the xCELLigence system (43 and 54 μM for PaCa-2
and Panc-1 cells), therefore we used the xCELLigence system to monitor the adhesion of
PaCa-2 and Panc-1 cells. Adhesion of the cells was blocked at doses greater than 33.75μM
(Figure 1D). The CI value was reduced by 50% in both cell lines at 67.5 μM between 8 – 12
h. Doses that blocked proliferation also had a dramatic effect on the cells’ ability to adhere
to the plate. The sensitivity of the xCELLigence system demonstrates the effects of APE1/
Ref-1 redox inhibition on proliferation, adherence, and morphology.
To investigate whether the cells were undergoing apoptosis following treatment with E3330,
we utilized two methods: Annexin / PI staining and PARP-1 cleavage (Figure 1C). Both
assays demonstrated similar results showing that although we had a reduction in
proliferation, there was not a corresponding increase in apoptosis. These data are consistent
with the idea that inhibition of the redox function of APE1/Ref-1 affects the cells’
proliferative capacity while the DNA repair function is critical for cell survival.(4)
Inhibition of the redox function of APE1/Ref-1 via E3330 arrests cell cycle progression
Using BrdU incorporation assays, the percentage of PaCa-2 and Panc-1 cells in S phase is
significantly decreased following treatment with E3330 (Figure 2A). DMSO, the vehicle
control, does not differ significantly from the media (data not shown). Furthermore, we
synchronized PaCa-2 cells and monitored re-entry into cell cycle following treatment with
E3330. At 8 h after adding serum-containing media, 60% less cells have entered S phase
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(Supp. Fig. 1), demonstrating that progression out of G1 is slower in the PaCa-2 cells when
the redox function of APE1/Ref-1 is inhibited.
We quantitated the levels of endogenous cell cycle inhibitors, p21 and p27 (Figure 2B, C).
While we observe no change in p27 levels, the levels of p21 increase 2 - 2.5 fold in cells that
have been treated with E3330. The effects on cell cycle progression and levels of p21 and
p27 are very similar to our recent report of the effects of APE1/Ref-1 siRNA on PaCa-2 and
Panc-1 cells.(22) However, the increase in apoptosis that we observe when APE1/Ref-1
protein levels are decreased by siRNA is not observed when we inhibit the redox function of
APE1/Ref-1. These data suggest that the redox function of APE1/Ref-1 affects both cell
cycle progression and the time the cells take to traverse the cell cycle in pancreatic cancer
cells.
Inhibition of APE1/Ref-1 via E3330 results in a decrease in transcriptional activity for three
known targets of APE1/Ref-1 redox activity
To further characterize the redox function of APE1/Ref-1 on pancreatic cancer cell
signaling, we utilized transient luciferase assays. In these experiments, the luciferase gene
expression was driven by NFκB, HIF1, or AP-1 and normalized to Renilla gene expression
for transfection efficiency. Inhibition of APE1/Ref-1 via E3330 results in a dose-dependent
reduction in NFκB, HIF1, and AP-1 activity in vitro (Figure 3, A-C). HIF1 activity was
induced by exposure to hypoxia for 24 hrs prior to luciferase assay. The basal levels of AP-1
activity in PaCa-2 are ~20-fold lower than the basal activity in Panc-1 cells and we were
unable to detect a significant decrease in activity with the low levels of basal activity in
PaCa-2 cells (data not shown). The doses of E3330 required to inhibit 50% of promoter
activity were ~67.5μM for NFκB and HIF1 and ~15μM for AP-1. To further demonstrate
that inhibition of APE1/Ref-1 blocks downstream signaling of HIF1, we treated Panc-1 and
PaCa-2 cells with E3330 for 24-h. We then analyzed HIF1 target, CA-IX(32) mRNA levels
using qRT-PCR assay. As predicted, there was a significant dose-dependent decrease in
HIF1 target, CA-IX mRNA in pancreatic cancer cells following APE1/Ref-1 inhibition (Fig.
3D). Because inhibition of mRNA for CA-IX serves as a biomarker for HIF1 activity(32),we
hypothesize that inhibition of APE1/Ref-1’s redox function by E3330 could disable the
tumors’ ability to respond to hypoxic conditions which is known to contribute to the
chemotherapeutic resistance of these tumors.
Blockade of APE1/Ref-1 redox activity diminishes the pancreatic cancer cells ability to
induce HIF1α and NFκB
We generated PaCa-2 and Panc-1 lines that stably express NFκB-driven and HIF1–driven
luciferase/GFP using lentiviral constructs, pGreenFire (pGF) from System Biosciences Inc.
As a negative control, stable cell lines were generated that contain the luciferase/GFP
cassette but do not have the NFκB or HIF1 response element (pGF-mCMV). Inhibition of
the redox function of APE1/Ref-1 blocks the ability of PaCa-2 and Panc-1 cells to induce
NFκB through TNFα (Figure 4A, B) as well as HIF1 activity (Figure 4C). PaCa-2 and
Panc-1 cells that express pGF-mCMV did not show detectable luciferase activity above
baseline and treatment with TNFα or hypoxia did not induce expression of luciferase
activity (data not shown).
Inhibition of APE1/Ref-1 redox activity delays the growth of pancreatic cancer xenografts
in vivo and exhibits favorable pharmacokinetic parameters
The estimated half-life (t ½) of E3330 was 3.7hrs. (Figure 5A). From this, a dosing regimen
was established in mice that consisted of two doses of E3330 each day, approximately 8-h
apart. As shown in Figure 5B, two dosages of E3330 maintained the concentrations of
E3330 ≥1 μM for over 24-h. In formulation studies, E3330 was dissolved in 4%
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CremophorEL: EtOH (1:1) in saline or 0.5% methylcellulose. Both vehicles were similar in
their PK levels in plasma and tumor tissue (Supplemental Fig. 2) and replaced the less
desirable vehicle, DMSO. Concentrations of E3330 attained in the blood of mice are within
the required range for target inhibition from in vitro studies suggesting that E3330 has
favorable properties in vivo.
Next we evaluated the anti-tumor efficacy of E3330 using both patient-derived tumors and
xenografts from established cell line, PaCa-2. In contrast to vehicle-control tumors, both
patient-derived and PaCa-2 xenografts demonstrated a significant tumor growth delay
(Figure 5C). All animals treated with E3330 had detectable drug in the tumor tissue (40
-7500 ng/g tissue). E3330 was detectable in pancreas, liver, lung, kidney, heart, and brain,
but was not overly toxic to the animals as measured by weight loss and bone marrow
cellularity (data not shown and Supplemental Fig. 2A, B). Furthermore, Ki67 staining is
reduced in E3330-treated tumors at Day 7 and Day 11 supporting the notion that APE1/
Ref-1 redox activity is blocking proliferation of the tumor cells (Supplemental Fig. 2C).
Another patient-derived xenograft was utilized and did not show the dramatic growth delay
that we observe in Figure 5C. However, tumor tissue analysis indicated that levels of E3330
in the unresponsive tumors were 10-fold less than in the Panc 253 responsive tumors:
2500ng/g (~6.6μM) versus 250ng/g (~0.7μM), data not shown. These results indicate that if
we can efficiently deliver APE1/Ref-1 redox inhibitor, tumor growth is strongly inhibited.
DISCUSSION
Although today’s standard of care for pancreatic cancer strives for a cure, debulking surgery
along with chemotherapy and/or radiation is almost always palliative rather than curative,
with few cases of long-term regression.(33) Researchers agree that pancreatic cancer defies
most of what we have come to know about other types of cancer; therefore, a different
therapeutic approach is needed.(1, 33, 34) Blocking a single step in a pathway or a single
pathway has very limited clinical utility in the face of the tumors’ cumulative defects. Jones
et al. found that pancreatic cancers contain a core set of 12 cellular signaling pathways and
processes, each of which was altered in 67 to 100% of the tumors analyzed.(24) Novel
targets that modulate multiple pathways may offer the most promise for clinical utility
against this dreaded disease. Transcription factors including NFκB, AP-1, and HIF1 are key
in the regulation of multiple signals in pancreatic cancer which provides strong evidence for
investigating the effects of targeting APE1/Ref-1 to kill pancreatic cancer cells. In this
report, we show that inhibition of APE1/Ref-1 reduces the proliferation of ectopic pancreatic
tumors in mice using both established pancreatic cancer cell lines and primary human
pancreatic tumors. Inhibition of APE1/Ref-1 redox activity led to cell cycle arrest and a
reduction in NFκB, AP-1, and HIF1 activity, key regulators of pathways that are involved in
the progression, maintenance, invasive and metastatic potential of pancreatic cancer.(5,
35-37) Furthermore, we show down-regulation of HIF1 target, CA-IX and surmise that
APE1/Ref-1 inhibition may be able to sensitize these tumors to therapy by disabling their
response to the hypoxic environment in which they are growing.
We recently demonstrated that human adenocarcinoma and peri-pancreatic metastases have
a significant increase in APE1/Ref-1 expression in adenocarcinoma as compared to normal
pancreas tissue.(22) The experiments described here and our previous work showing both in
vitro and in vivo data support APE1/Ref-1 as a viable target in this deadly disease.(21, 22)
We utilized the redox-specific APE1/Ref-1 inhibitor, E3330, which recognizes an alternate,
redox active conformation of APE1/Ref-1, and potentially inhibits its redox activity by
inducing disulfide bond formation.(16, 17) Biochemical studies using radiolabeled E3330
and proteins renatured on membrane blots demonstrated that 14C-labeled E3330 very
selectively bound to both recombinant APE1/Ref-1 and purified APE1/Ref-1 from cell
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nuclear extracts.(20) While E3330 blocks Ref-1’s redox function, it has no effect on APE1/
Ref-1 endonuclease activity or BER activity of an AP site.(5) These studies formally
demonstrate the specificity of E3330 for APE1/Ref-1’s redox activity, without impacting on
its DNA repair function. The PK/PD studies (Figure 5) demonstrate that tumors with
significant levels of E3330 have their rate of growth significantly reduced. We are currently
investigating additional delivery methodology such as nanoparticle technology to ensure
efficient delivery of APE1/Ref-1 inhibitor as well as novel compounds with sub-micromolar
inhibition of APE1/Ref-1 redox activity. Another potential mechanism for the different
amount of E3330 in these two patient-derived tumors is that the drug is pumped out of the
cells. For example, there are several ATP-binding cassette transporters in the MDR/MRP
gene family. Given the chemical structure of E3330, we predict that it is not a substrate for
P-gp (MDR1, ABCB1) since this efflux transporter typically binds cationic, lipophilic
structures. However, E3330 could be a substrate for MRP (ABCC1) or BCRP (ABCG2), as
these transporters are known to bind anionic substrates including glutathione conjugates.(38)
However, it should be noted that MRP is not always associated with extracellular transport,
but may concentrate substrates into intracellular vesicles, thus protecting potential targets
from drug. This is one possibility for the tumors with low levels of E3330 detected.
However, further research is warranted.
The mechanism of action of E3330 is through the blockage of the transcriptional regulation
of APE1/Ref-1 therefore, it blocks activity of NFκB, AP-1, and HIF1 as shown in Fig. 3, 4.
These data provide fundamental evidence that E3330 inhibits three known transcriptional
targets of APE1/Ref-1 in pancreatic cancer cells. Pancreatic tumors are characterized as one
of the most hypoxic tumors that clinicians encounter.(3, 35) Our previous work and the data
here demonstrate that blockade of APE1/Ref-1 redox signaling does affect the activity of
HIF1 in pancreatic cancer cells. (21, 23) This supports our hypothesis that inhibition of
APE1/Ref-1 could disable the tumors’ ability to respond to hypoxic conditions which
contributes to chemotherapeutic resistance. Using in vitro luciferase-based assays, E3330
can inhibit the activity of these three important transcription factors in pancreatic cancer.
Using a lentiviral system, we created stable cell lines with a construct containing an NFκB
or HIF1 response element which drives GFP and luciferase. In PaCa-2 and Panc-1 cells that
express luciferase driven by the NFκB or HIF1 promoter, E3330 treatment results in a
reduction in activity as shown by reduction of GFP positivity and luciferase activity (Figure
4 and data not shown). Inhibition of NFκB (with and without induction by TNFα) and HIF1
activity is observed both in transient and stable luciferase assays. Decreases in the activity of
downstream transcription factors provide important support for APE1/Ref-1 as a target in
pancreatic cancer. We can now use these stable cell lines in vivo as markers of NFκB, AP-1,
and HIF1 and dissect which of these transcription factors are critical for the survival and
spread of pancreatic cancer.
Inhibition of APE1/Ref-1 via E3330 inhibits the growth of pancreatic tumor xenografts, both
the cell line as well as xenograft models, and we plan to extend our studies to orthotopic
models. In addition to evaluating E3330 as a single agent, combination of E3330 with
Gemcitabine will also be tested to know whether E3330 potentiates Gemcitabine sensitivity.
A reduction in APE1/Ref-1 protein expression does indeed sensitize pancreatic cells in vitro
to gemcitabine(39) suggesting that combination therapy might be useful in treating this
disease. Due to the decrease in proliferative capacity and the decrease in cells in S phase
(Figure 1, 2), careful selection of the agent(s) that are chosen for combination therapy as
well as the dosing schedules should be chosen carefully. The studies here provide pre-
clinical validation for a novel therapeutic strategy for this largely incurable cancer.
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Abbreviations List
AP Apurinic/apyrimidinic
AP-1 Activator protein-1
APE1/Ref-1 AP endonuclease1/Redox factor-1
AUC area under the curve
AUMC area under the moment curve
ATP adenosine-5′-triphosphate
BER base excision repair
CA-IX carbonic anhydrase-IX
Cmax maximum plasma concentration
CI cell index
HIF1α hypoxia-inducible factor 1, alpha subunit
mCMV mouse cytomegalovirus
NFkB Nuclear Factor kappa b
PCEC pancreatic cancer-associated endothelial cells
pGF pGreenFire
PD pharmacodynamic properties
PK pharmacokinetic
PI propidium iodide
Redox reduction-oxidation
Ref-1 Redox effector factor 1
RLU relative luciferase units
tmax time of Cmax
Vdss volume of distribution
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Figure 1.
Inhibition of APE1/Ref-1 redox activity blocks the proliferation and adhesion of pancreatic
cancer cells without inducing apoptosis. A, Cells were counted in triplicate using Trypan
Blue after 48-h (Panc-1) or 72-h (PaCa-2) of E3330 exposure. Day 0 refers to the cell
number 24-h after plating. xCELLigence DP system was used to determine cell growth (B)
and adhesion (D) after E3330 treatment. Assays were performed in triplicate, three
individual times with a representative experiment shown. C, Histogram plots (The x-axis
represents Annexin-488 staining and the y-axis represents PI staining, Top) and Western blot
(Bottom) probed with PARP-1 after treatment with increasing concentrations of E3330 for
48 hours (FL, full length).
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Figure 2.
Inhibition of APE1/Ref-1 redox activity alters cell cycle profile and levels of p21 protein. A,
Representative dot plots of BrdU assays in Panc-1 (Top) and PaCa-2 cells (Bottom) treated
with E3330. The x-axis represents 7-AAD staining and the y-axis represents BrdU-FITC
staining. Western blots of cell-cycle proteins, p21, p27, and tubulin as loading control in
PaCa-2 (B) and Panc-1 (C). Bar graphs demonstrate quantitation of ≥ 3 independent
experiments with average +/− SE. * p < 0.05 using Student’s t-test, comparing DMSO vs.
E3330.
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Figure 3.
E3330 inhibits the activity of NFκB, HIF1, and AP-1 in a cell-based reporter assay. A – C,
Panc-1 and PaCa-2 cells were transfected with NFκB, HIF1, or AP-1–Luc construct and
cotransfected with a Renilla vector, pRL-TK. After 16-h, cells were treated with E3330 for
24-h, and Firefly and Renilla luciferase activities were assayed using Renilla luciferase
activity for normalization. All transfection experiments were performed in triplicate and
repeated at least 4 times in independent experiments. Data are expressed as Relative
Luciferase Units (RLU) normalized to DMSO showing the mean ± SE. Student’s t tests
were performed, and * p < 0.05 level comparing DMSO to E3330. D) qPCR analysis of CA-
IX expression following E3330 treatment and hypoxia. Expression in Panc-1 cells was
normalized to DMSO in normoxia (left). However, basal levels of CA-IX were undetectable
in PaCa-2 cells in normoxia, therefore the CA-IX expression was normalized to DMSO
under hypoxia (right). Shown is one representative experiment. Samples were run in
triplicate and experiment performed in both cell lines in duplicate.
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Figure 4.
E3330 inhibits NFκB and HIF1 transactivation in stable luciferase-expressing cell lines. A,
PaCa-2 cells pGF-NFκB or pGF-mCMV were treated with E3330 for 24-h, followed by
TNFα (50ng/mL, 6-h). Green cells indicate induction of NFκB which is blocked by
treatment with E3330. B, NFκB activity of cells induced with TNFα, M = media control
which shows basal NFκB activity. C, HIF1 activity of cells following E3330 treatment.
Firefly luciferase activity was assayed as above and normalized to MTS assay data and then
to vehicle control. Experiments were performed in triplicate and repeated at least 3 times in
independent experiments. Student’s t tests were performed, and * p < 0.05 level comparing
DMSO to E3330.
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Figure 5.
E3330 pharmacokinetic profile and analysis of tumor growth rate in PaCa-2 and patient-
derived xenografts. A, Serum concentrations of E3330 following one dose at 25 mg/kg, ip in
9% DMSO; B, Serum concentrations of E3330 (25 mg/kg, ip, 9% DMSO) following dosing
at 0-h and 8-h as indicated by the arrows. C, Tumor growth delay following treatment with
E3330 in PaCa-2 xenografts (left) and patient-derived tissue, Panc253 (right).
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